Apparatus and method for isolating leukocytes and tumor cells by filtration

US9535052B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9535052-B2
Application numberUS-201313961847-A
CountryUS
Kind codeB2
Filing dateAug 7, 2013
Priority dateFeb 17, 2011
Publication dateJan 3, 2017
Grant dateJan 3, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides novel apparatuses and methods for isolating or recovering a subset of blood cells such as leukocytes and/or circulating tumor cells from blood samples by filtration without changing the intracellular concentration of a therapeutic agent such as an anticancer drug. Contrary to the art, the apparatuses and methods of the present invention advantageously provide cell lysates from recovered cells such as leukocytes and/or circulating tumor cells without substantial dilution of a therapeutic agent such as an anticancer drug.

First claim

Opening claim text (preview).

What is claimed is: 1. An apparatus for isolating and separating leukocytes from red blood cells in a whole blood sample, said apparatus comprising: a filtration device comprising an upper chamber, which is a cylindrical tube, a lower chamber, which is a cylindrical tube, and one or more stacked filter membranes between said upper and lower chambers, wherein said one or more stacked filter membranes are capable of retaining said leukocytes, wherein the inner diameters of the upper and lower chambers are similar as to create a cylindrical tube which allows liquids to pass therethrough, wherein said one or more stacked filter membranes is placed between screw threads of the upper chamber and lower chamber, which chambers are securely attached together; and a collection tube for collecting red blood cells from said whole blood sample, wherein said filtration device is placed on top of said collection tube, and wherein said red blood cells are separated from said leukocytes and collected in said collection tube following centrifugation. 2. The apparatus of claim 1 , wherein said whole blood sample is loaded into said upper chamber of said filtration device. 3. The apparatus of claim 1 , wherein said filtration device comprises two, three, or four stacked filter membranes. 4. The apparatus of claim 1 , wherein said upper chamber further comprises a snap-cap lid attached thereto. 5. The apparatus of claim 4 , wherein the snap-cap lid is tethered via a strap to the upper chamber. 6. The apparatus of claim 1 , further comprising a second collection tube. 7. The apparatus of claim 6 , wherein said second collection tube contains lysis buffer. 8. The apparatus of claim 1 , wherein said whole blood sample is obtained from a subject having or suspected of having a hematological malignancy. 9. The apparatus of claim 8 , wherein said hematological malignancy is chronic myelogenous leukemia (CML). 10. The apparatus of claim 8 , wherein said subject is either receiving or not receiving therapy with a therapeutic agent. 11. The apparatus of claim 10 , wherein said therapeutic agent is an anticancer drug. 12. The apparatus of claim 11 , wherein said anticancer drug is selected from the group consisting of a tyrosine kinase inhibitor, chemotherapeutic agent, hormonal therapeutic agent, radiotherapeutic agent, monoclonal antibody, vaccine, and combinations thereof. 13. The apparatus of claim 12 , wherein said tyrosine kinase inhibitor is selected from the group consisting of imatinib mesylate nilotinib, dasatinib, bosutinib, gefitinib, sunitinib, erlotinib, lapatinib, canertinib, semaxinib, vatalanib, sorafenib, leflunomide, vandetanib, and combinations thereof. 14. The apparatus of claim 1 , wherein said leukocytes are selected from the group consisting of normal leukocytes, malignant leukocytes, diseased leukocytes, and combinations thereof. 15. The apparatus of claim 1 , wherein said apparatus is a plurality of filtration devices. 16. The apparatus of claim 1 , wherein said upper chamber is a cylindrical tube with male helical ridges or threads. 17. The apparatus of claim 16 , wherein the threads of the upper chamber fit securely into female grooves of the lower chamber. 18. The apparatus of claim 1 , a filtration device wherein the upper chamber and the lower chamber are screwed together. 19. A method for preparing a lysate of leukocytes from a whole blood sample without substantial dilution of a therapeutic agent, said method comprising: (a) loading said whole blood sample into an apparatus of claim 1 ; (b) centrifuging said apparatus to capture said leukocytes on said one or more stacked filter membranes and to separate said red blood cells into said collection tube; and (c) lysing said leukocytes captured on said one or more stacked filter membranes with lysis buffer but without a wash step between steps (b) and (c) to thereby prepare a lysate of leukocytes. 20. The method of claim 19 , further comprising replacing said collection tube with a second collection tube between steps (b) and (c). 21. The method of claim 20 , further comprising centrifuging said apparatus containing said second collection tube after lysing said leukocytes in step (c) and collecting said lysate of leukocytes in said second collection tube. 22. The method of claim 19 , wherein said whole blood sample is obtained from a subject receiving a therapeutic agent. 23. The method of claim 22 , wherein said a therapeutic agent is an anticancer drug. 24. The method of claim 19 , wherein said whole blood sample is incubated in vitro with a therapeutic agent prior to loading into said apparatus. 25. The method of claim 19 , wherein the expression and/or activation level of at least one oncogenic fusion protein and/or signal transduction molecule is measured in said lysate of leukocytes. 26. The method of claim 25 , wherein the at least one oncogenic fusion protein comprises BCR-ABL. 27. The method of claim 19 , wherein said wherein said apparatus is a plurality of filtration devices.

Assignees

Inventors

Classifications

  • filtration · CPC title

  • A61M1/029Primary

    Separating blood components present in distinct layers in a container, not otherwise provided for (containers for storing blood or blood components A61J1/05; sampling or analysing blood by separating blood components G01N33/491) · CPC title

  • Test tubes specially adapted for centrifugation purposes · CPC title

  • by other techniques involving separation of suspended solids · CPC title

  • White blood cells; Leucocytes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9535052B2 cover?
The present invention provides novel apparatuses and methods for isolating or recovering a subset of blood cells such as leukocytes and/or circulating tumor cells from blood samples by filtration without changing the intracellular concentration of a therapeutic agent such as an anticancer drug. Contrary to the art, the apparatuses and methods of the present invention advantageously provide cell…
Who is the assignee on this patent?
Nestec Sa
What technology area does this patent fall under?
Primary CPC classification A61M1/029. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).